老年人血液中血管紧张素Ⅱ水平与认知功能及内侧颞叶萎缩的相关性研究

doi:10.3969/j.issn.1003-9198.2022.07.009

摘要/Abstract

摘要： 目的探讨老年人血液中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)水平与认知功能及内侧颞叶萎缩(MTA)的相关性。方法共入组老年AD病人(AD组)40例,老年认知功能正常者(对照组)40例。所有参与者均完成中文版Addenbrooke认知评估量表Ⅲ(ACE-Ⅲ)、MMSE、日常生活能力评定量表(ADL)评估及24 h血压水平监测,并完成头颅MRI检查,予经典MTA评分。采用酶联免疫吸附法检测血浆AngⅡ水平。AngⅡ与认知功能及MTA评分的相关性采用Pearson相关系数描述。结果 AD组的年龄、血浆AngⅡ水平、MTA评分显著高于对照组,MMSE、ACE-Ⅲ、ADL评分显著低于对照组,差异均有统计学意义(P<0.05),2组SBP、DBP水平差异无统计学意义(P>0.05)。AngⅡ水平与MMSE、ACE-Ⅲ、ADL评分无明显相关性(P>0.05),与MTA评分呈正相关性(r=0.228,P<0.05),且这种相关性与血压水平无关。结论老年AD病人血液中AngⅡ水平高于认知功能正常者,而且老年人AngⅡ水平升高与内侧颞叶萎缩具有一定相关性。

关键词: 阿尔茨海默病, 血管紧张素Ⅱ, 认知功能, 内侧颞叶萎缩

Abstract: Objective To investigate the associations of angiotensin Ⅱ (AngⅡ) level with cognitive function and medial temporal atrophy (MTA) in the elderly. Methods Forty elderly patients with Alzheimer's disease (AD group) and 40 elderly with normal cognitive function (control group) were enrolled. All the subjects were evaluated by Chinese version of Addenbrooke's Cognitive Examination Ⅲ (ACE-Ⅲ), Mini-Mental State Examination (MMSE) and Activities of Daily Living Scale (ADL), and 24-hour blood pressure was measured. All the subjects were rated by medial temporal atrophy (MTA) scale on MRI. The level of AngⅡ was measured by enzyme-linked immunosorbent assay. Pearson correlation analysis was performed to evaluate the associations of AngⅡ level with cognitive function and MTA. Results The age, AngⅡ level, MTA score were significantly higher, and the scores of MMSE, ACE-Ⅲ and ADL were significantly lower in the AD group than those in the control group (P<0.05). There were no significant differences in the levels of systolic blood pressure and diastolic blood pressure between the two groups (P>0.05). The level of AngⅡ was not related to the scores of MMSE, ACE-Ⅲ and ADL (P<0.05), but positively correlated with MTA (r=0.228, P<0.05), and further study showed the correlation was not mediated by blood pressure. Conclusions The level of AngⅡ in the elderly patients with AD is higher than that in the normal elderly, and the increased level of AngⅡ is associated with MTA.

Key words: Alzheimer's disease, angiotensin Ⅱ, cognitive function, medial temporal atrophy

中图分类号:

R749.16

王变荣, 郑慧芬, 徐畅, 张荷笛, 黄丹青, 田琦, 陈春苗. 老年人血液中血管紧张素Ⅱ水平与认知功能及内侧颞叶萎缩的相关性研究[J]. 实用老年医学, 2022, 36(7): 684-687.

WANG Bian-rong, ZHENG Hui-fen, XU Chang, ZHANG He-di, HUANG Dan-qing, TIAN Qi, CHEN Chun-miao. Associations of angiotensin Ⅱ level with cognitive function and medial temporal atrophy in elderly[J]. Practical Geriatrics, 2022, 36(7): 684-687.

参考文献

[1] YU J T, XU W, TAN C C, et al. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials[J]. J Neurol Neurosurg Psychiatry, 2020, 91(11):1201-1209.
[2] ITURRIA-MEDINA Y, SOTERO R C, TOUSSAINT D J, et al. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis[J]. Nat Commun, 2016, 7:11934.
[3] ASHBY E L, KEHOE P G. Current status of renin-aldosterone-angiotensin system targeting antihypertensive drugs as therapeutic options for Alzheimer's disease[J]. Exp Opin Investig Drugs, 2013, 22(10):1229-1242.
[4] SCOTTI L, BASSI L, SORANNA D, et al. Association between renin-angiotensin- aldosterone system inhibitors and risk of dementia: a meta-analysis[J]. Pharmacol Res, 2021, 166: 105515.
[5] INABA S, IWAI M, FURUNO M,et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice[J]. Am J Hypertens, 2009, 53(2):356-362.
[6] KEHOE P G, HIBBS E, PALMER L E,et al. Angiotensin-Ⅲ is increased in Alzheimer's disease in association with amyloid-β and tau pathology[J]. J Alzheimers Dis, 2017, 58(1):203-214.
[7] TAKEDA S, SATO N, OGIHARA T,et al. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential[J]. Front Biosci, 2008, 13:2253-2265.
[8] SCHELTENS P, LEYS D, BARKHOF F, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates[J]. J Neurol Neurosurg Psychiatry, 1992, 55(10):967-972.
[9] JOCHEMSEN H M, TEUNISSEN C E, ASHBY E L,et al. The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease[J]. Alzheimers Res Ther, 2014, 6(3):27.
[10] JOCHEMSEN H M, VAN DER FLIER W M, ASHBY E L,et al. Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy[J]. J Alzheimers Dis, 2015, 44(1):153-162.
[11] YASAR S, VARMA V R, HARRIS G C,et al. Associations of angiotensin converting enzyme-1 and angiotensin Ⅱ blood levels and cognitive function[J]. J Alzheimers Dis, 2018, 63(2):655-664.
[12] CLAUS J J, STAEKENBORG S S, HOLL D C,et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: validation in a large memory clinic population[J]. Eur Radiol, 2017, 27(8):3147-3155.
[13] VISSER P J, VERHEY F R, HOFMAN P A, et al. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment[J]. J Neurol Neurosurg Psychiatry, 2002 ,72(4):491-497.
[14] DUBOIS B, FELDMAN H H, JACOVA C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG -2 criteria[J]. Lancet Neurol, 2014, 13(8):614-629.
[15] YASAR S, MOORED K D, ADAM A, et al. Angiotensin II blood levels are associated with smaller hippocampal and cortical volumes in cognitively normal older adults[J]. J Alzheimers Dis, 2020, 75(2):521-529.